Chemotherapy Use and Survival in Small-Cell Lung Cancer
Author Information
Author(s): Rich A L, Tata L J, Free C M, Stanley R A, Peake M D, Baldwin D R, Hubbard R B
Primary Institution: University of Nottingham
Hypothesis
How do patient and hospital features influence outcomes in small-cell lung cancer in England?
Conclusion
Patients first seen at a hospital with a keen interest in clinical trials are more likely to receive chemotherapy, and chemotherapy was associated with improved survival.
Supporting Evidence
- 61% of patients received chemotherapy.
- Older age and comorbidity reduced the likelihood of receiving chemotherapy.
- Chemotherapy was associated with a lower mortality rate.
Takeaway
This study found that older patients and those with more health issues are less likely to get chemotherapy for lung cancer, but getting chemotherapy helps people live longer.
Methodology
The study linked the National Lung Cancer Audit and Hospital Episode Statistics and used multiple logistic and Cox regression analyses.
Potential Biases
The study may not account for patients who were offered chemotherapy but declined.
Limitations
Data on comorbidity were limited to only six disease groups and may not capture all relevant conditions.
Participant Demographics
54% of patients were men, with a median age of 69 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 1.06, 1.90
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website